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Abstract: The modulation of neuronal cell firing is mediated by the release of the neurotransmitter
GABA (γ-aminobuytric acid), which binds to two major families of receptors. The ionotropic
GABAA receptors (GABAA Rs) are composed of five distinct subunits that vary in expression by brain
region and cell type. The action of GABA on GABAA Rs is modulated by a variety of clinically and
pharmacologically important drugs such as benzodiazepines and alcohol. Exposure to and abuse
of these substances disrupts homeostasis and induces plasticity in GABAergic neurotransmission,
often via the regulation of receptor expression. Here, we review the regulation of GABAA R subunit
expression in adaptive and pathological plasticity, with a focus on substance use. We examine the
factors influencing the expression of GABAA R subunit genes including the regulation of the 50 and
30 untranslated regions, variations in DNA methylation, immediate early genes and transcription
factors that regulate subunit expression, translational and post-translational modifications, and other
forms of receptor regulation beyond expression. Advancing our understanding of the factors
regulating GABAA R subunit expression during adaptive plasticity, as well as during substance use
and withdrawal will provide insight into the role of GABAergic signaling in substance use disorders,
and contribute to the development of novel targeted therapies.
Keywords: GABA; GABAA receptor; expression; transcription; translation; substance use; substance
use disorder; alcohol; benzodiazepines; plasticity

1. Introduction
Neuronal firing patterns in the brain are powerfully modulated by the inhibitory neurotransmitter
γ-aminobutyric acid (GABA). GABAA receptors (GABAA Rs) are ligand-gated ion channels that mediate
the majority of fast inhibitory neurotransmission in the brain, and GABAA R dysfunction is tied to many
neurological and psychiatric illnesses, such as anxiety, epilepsy, and the development of substance
use disorder. GABAA Rs are heteropentamers consisting of five distinct subunits that vary in their
expression by brain region, cell type, and subcellular domain, as well as in their function. There are at
least 19 receptor subunits, grouped by homologous amino acid sequences into subclasses: α1–6, β1–3,
and γ1–3, δ, ε, π, θ, and ρ1–3 [1]. While the combination and function of receptor subunits varies,
most are comprised of two α-, two β-, and one γ- [2,3]. GABAA R subunit expression is also temporally
regulated, with the expression of GABAA R subunit α2, α3, α5, and β3 mRNA predominating during
early development, which are superseded by α1, α4, β2 and δ subunit mRNAs in the adult brain [4].
These changes coincide with the switch in the reversal potential for chloride, transitioning GABA from
being depolarizing to hyperpolarizing [4,5].
α subunits in particular are important determinants of receptor localization and function.
GABAA Rs composed of α1β2γ2 are the most widely expressed in the adult brain, with α1 being the
most highly expressed subunit [2,4,6]. While α1, β1-3, and γ2 immunoreactivities are found throughout
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the brain, α2 subunit containing receptors are enriched in the cerebellum and forebrain including the
hippocampus, α3 containing receptors are cortically enriched, α4 containing receptors are enriched
in the striatum and thalamus, and α5 containing receptors are enriched in the olfactory bulbs and
hippocampus, while α6 immunoreactivity is relatively restricted to cerebellar granule cells and the
cochlear nucleus [7,8].
α subunit expression also varies by subcellular localization, with α1–3 being predominantly
enriched at synaptic sites, while α4–6 are often localized extrasynaptically [9]. Synaptic GABAA Rs
are also targeted to multiple synapse subtypes where interneuron presynaptic compartments contact
the dendrites, the soma, or the axon initial segment. The clustering of specific GABAA R subtypes
to synaptic and extrasynaptic subcellular domains is thought to be regulated by subunit-specific
interactions with scaffolding proteins including gephyrin, collybistin, and dystrophin [10–12].
Differences in agonist affinity, gating and pharmacological properties have been repeatedly shown
by altering subunits of recombinant GABAA Rs [13–16]. Subunit composition also affects the potency
of GABA, as α2- and α3-containing receptors show low potency, α1-, α4-, and α5-containing receptors
show intermediate potency, and α6-containing receptors show high potency [17]. GABAA Rs are the site
of action for many clinically relevant drugs, most of which act as positive allosteric modulators of the
receptors and alter the phasic inhibition by prolonging the decay of inhibitory post-synaptic currents
(IPSCs), which in turn can prevent neural firing in response to concurrent excitatory stimuli [13,18].
The kinetics of IPSCs at the postsynaptic GABAA R is determined by biophysical properties such as
the subunit composition and how they cluster at the cell membrane [18]. The specific α subunit is a
determining factor in receptor function and setting the kinetics of IPSCs [13,18–20].
GABAergic signaling is controlled at the cellular level by changes in neurotransmitter synthesis,
vesicular storage, neurotransmitter release and re-uptake, and postsynaptic receptor clustering [1].
GABAergic signaling at the cellular level is often modulated by changes in the expression of
GABAA Rs. GABAA R gene expression is temporally regulated throughout development and the
life span, as well as in response to experience, substance use, and as a result of a number of
neuropathologies [4,21,22]. The expression of genes encoding the GABAA R subunits can be altered
at multiple levels including transcription initiation, alternative splicing, mRNA stability, translation,
post-translational modifications, intracellular tracking and protein degradation [1] (Figure 1). In the
present review, we will discuss what is known about the regulation of GABAA R expression across the
levels in both normal and pathological states, with a focus on substance use and withdrawal.
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Figure 1. Levels of regulation impacting GABAA R expression and function. Expression of a GABAA R
subunit begins with the initiation of transcription, which is controlled by a multiprotein complex that
regulates the 50 UTR flanking genes encoding individual subunits. Transcription factors and other
proteins that regulate transcription (yellow) bind to consensus sites in the 50 UTR and either promote
or repress initiation. Many GABAA R subunit 50 UTRs contain consensus sites for more than one
transcription factor, as well as multiple transcription start sites (red). Additional phases of splicing
and polyadenylation (green) occur in the nucleus prior to the shuttling of the transcript to the rough
endoplasmic reticulum for translation at ribosomes (grey circles). Translation of the subunit transcripts
has been shown to be regulated by RNA-binding proteins (RBPs; turquoise), as well as microRNAs
(miRNAs; turquoise). Once translated, the subunits are assembled (blue) together in quaternary
structure to form a functional heteropentameric GABAA R. GABAA Rs are also subject to regulation
via post-translational modifications (blue) such as phosphorylation and palmitoylation, as well as
regulated targeting and trafficking to become preferentially localized to specific subcellular domains.

2. Basal Mechanisms Regulating GABAA Receptor Expression: Transcription, Translation,
and Beyond
In order to understand the dynamic regulation of GABAA R expression in substance use, it will be
important to examine the mechanisms that regulate subunit expression under basal physiological states.
The examination of the factors that regulate transcription, translation and beyond reveals numerous
levels of regulation, allowing for the precise tuning of GABAA R expression. In the following section,
we summarize what is known about the transcription factors, epigenetic regulators, and RNA-binding
proteins modulating GABAA R subunit expression.
The evolution of GABAA Rs and their subunits is highly accessible using a phylogenetic tree and
the direct examination of gene organization on chromosomes [23]. Many of the subunit genes are
organized in β-α-α-γ and β-α-γ clusters on different chromosomes, thought to have evolved from a
single ancestral β-α-γ cluster [1,23]. In total, four clusters of genes coding for GABAA R subunits have
been found in humans, and this organization is thought to be possibly involved in coordinated gene
regulation [1,24]. The genes encoding β1, α2, α4, and γ1 (GABRB1; GABRA2; GABRA4; GABRG1) are
all clustered on chromosome 4p14-q12 in humans [25,26]. The β1, α2, and α4 subunits are all enriched
in the hippocampus of the adult rat, which may indicate that cluster organization may be necessary
for maintaining region-specific expression [1,6]. Chromosome 5q32.1-q35 contains the cluster coding
for the most common GABAA R subunits β2-α1-α6-γ2 [27] (GABRB2; GABRA1; GABRA6; GABRG2),
again suggesting that the clustering of subunit genes plays a role in the regulation of expression,
and that common factors may regulate the expression of multiple subunit genes.
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2.1. Transcription
A primary control on mRNA levels and gene expression is transcription initiation, which requires
the orchestration of multiple transcription factors and other DNA-binding proteins that recognize
discrete motifs surrounding the gene, often in untranslated regions (UTRs) [28]. In active chromatin,
conserved DNA motifs flanking the 50 end of genes interact with a diverse set of DNA-binding proteins
(Figure 1) that change in response to diverse physiological stimuli. Using genetic approaches in yeast
and Drosophila, as well as biochemical assays in mammalian cells, large families of sequence-specific
activators and accessory factors have been identified that help form the RNA Pol II complex necessary for
the initiation of transcription [28]. Despite many advances in our global understanding of transcription
control, very little is known about the detailed and elaborate regulation of specific individual genes [28],
including the genes encoding GABAA R subunits.
In silico analysis and experimentation have been use to examine the promoters of GABAA R
subunit genes, including the prediction of core elements, possible proximal transcription factors,
as well as transcription start sites (Figure 2) [29,30]. The analysis of alignments from multiple species
demonstrated a highly conserved 50 sequence flanking GABRA1, including a site for the binding of
specificity proteins (Sps), as well as a site for the binding of cAMP response element-binding protein
(CREB) [29]. Sps are zinc-finger transcription factors known to regulate the expression of many genes.
The neuron-specific transcription factor Sp4 has been shown to regulate the expression of GABRA1,
as well as excitatory neurotransmitter receptor genes [31]. CREB and inducible cAMP early repressor
(ICER) have been experimentally confirmed as transcriptional regulators of the α1 subunit [32]. CREB is
a stimulus-induced transcription factor that has been implicated in mechanisms of plasticity [32,33].
CREB has a well-established role in learning and memory [34], and has also been implicated in the
response to substance use [35,36].

Figure 2. Overview of the major regulators of transcription and translation influencing the expression
of GABAA R subunits. Generally, the 50 UTR of GABAA R subunit genes contains multiple consensus
sites for transcription factors (yellow), and in many cases, multiple transcription start sites (red).
The majority of subunits lack canonical TATA and CCAAT sequences in their 50 UTRs. A number of
regulators have been found to influence the transcription of multiple subunits including CREB and
MeCP2. Maturation of the mRNA involves the addition of a 50 cap as well as a poly-A tail adjacent to
the 30 UTR. Mature GABAA R transcripts are transported out of the nucleus to ribosomes on the rough
endoplasmic reticulum, where translation is influenced by RNA-binding proteins (blue oval) such as
FMRP, NONO, and Pum2, as well as by microRNAs (miRNAs; blue line).

The GABRA2 gene has been found to have multiple start sites, three promoter regions, and generate
six mRNA isoforms arising from alternative splicing of exons 1A, 1B, and 1C [37]. The exons
1A, 1B, and 1C showed between 61–78% homology to that found in the cloned human DNA [37,
38]. Alternative promoters are associated with developmental and tissue-specific gene regulation,
which may explain the six α2 isoforms, despite no detected difference in the α2 protein product [37].
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Nucleotide sequence analysis of these 50 -flanking regions of GABRA2 showed that all three of the
alternative promoters are located at guanine–phosphate–cytosine dinucleotide (GpC)-rich regions and
that two of the three lacked the typical TATA and CCAAT sequences. In silico comparison of rat and
human GABRA2 confirms a conserved Sp1 site in the 50 region flanking GABRA2 [29], which has been
experimentally confirmed to be regulated by the neuron-specific transcription factor Sp4 [31].
The GABRA3 gene is localized to chromosome X, and in a cluster with the GABRB4 gene [39].
In mice and humans, cDNA showed a similar intron–exon structure between GABRA3 and other
GABAA R subunit genes, with a highly unique promoter region containing GA repeats in the core
promoter [39]. Multiple repeats vary by species, appear to be random, and generally have minor
effects on transcription [39,40]. The GABRA3 gene appears to have several start sites, yet there is no
evidence for more than one promoter [29]. Examination of the GABRA4 promoter has identified two Sp
binding sites that bind Sp3 and Sp4, and are critical for the promoter activity in vivo [41]. The GABRA4
promoter also contains an early growth response protein (Egr) site that is highly conserved across
species [42], and Egr3 has been shown to regulate the change in α4 subunit expression following a
seizure [42]. Egr family members, especially Egr1, have been shown to be induced in the striatum
following substance use [43,44].
Other GABAA R subunits have alternative promoters that help to ensure a proper temporal
and spatial regulation of gene expression. The GABRA5 gene contains at least three different exons
in humans that are homologous to those in rats, suggesting an evolutionary importance of this
promoter [24]. The sequences of the alternative promoters of α5 are not homologous to those of
other GABAA R subunit promoters, however they do share in common a lack of the canonical TATA
and CCAAT boxes, and display cytosine–phosphate–guanine dinucleotide (CpG)-rich sequences [24].
The GABRA5 promoter contains putative sites for Sp binding, and an activator protein 2 (AP2) motif [29].
GABAA Rs containing the α6 subunit show a highly regulated expression restricted to the cerebellum,
and the examination of the 50 -UTR points to how this regulation is achieved. A region which enhances
GABRA6 gene expression exclusively in cerebellar granule cells has been found to contain a conserved
nuclear factor 1 (NF-1) -binding site [45,46]. Chromatin immunoprecipitation demonstrated that
NF-1 binds to the GABRA6 promoter, and NF1 deletion dramatically reduces the expression of α6 in
cerebellar granule cells [45].
In addition to the 50 UTR regulation of transcription, GABAA R subunit genes are also regulated by
influences on the gene body. For example, the 50 UTR as well as the GABRB3 gene contain binding sites
for methyl CpG-binding protein 2 (MeCP2). MeCP2 is a reader of methylation that recognizes and binds
5-methylcytosine. MeCP2 binding is predominantly thought to lead to the repression of transcription
through the slowing of polymerase [47], but has also been suggested to be an activator [48]. Loss of
function mutations in the MECP2 gene lead to the neurodevelopmental disorder Rett syndrome [49,50].
The examination of post mortem tissue from patients with Rett syndrome, and the neurodevelopmental
disorder Angelman syndrome, have shown a reduction in β3 subunit expression [50,51]. This finding is
supported in MeCP2-null mice where the β3 subunit is downregulated in the cerebellum. In addition,
it has been shown that the α1 subunit is downregulated in the frontal cortex, while α2 and α4 are
reduced in the ventrolateral medulla of the MeCP2-null model [51,52]. In an in vitro study, MeCP2
expression activated the expression of the GABAA R α1 subunit [53]. The regulation of multiple
GABAA R subunit expression patterns in tissue from Rett patients as well as models suggest that
MeCP2 may be a global transcriptional regulator of GABAA R subunit genes [53]. Epigenetic regulation
induced via the phosphorylation of MeCP2 has recently been implicated in the gene expression changes
that follow exposure to substances [54].
Globally, multiple GABAA R α subunit genes are flanked by 50 -UTRs that are GpC or CpG-rich
and lack the canonical TATA box (Figure 2). α subunit genes often have multiple promoters, start sites,
and contain consensus sequences for more than one transcription factor, suggesting a high degree of
regulation. Genes for β- and γ-subunits have shown similar features, with some (β1, β3, γ1) lacking the
canonical TATA box and being relatively well conserved across species. The elucidation of transcription
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controls on GABAA R subunit expression provides a basis for the generation of mechanistic hypotheses
regarding the spatial and temporal regulation of GABAA R subunit expression, yet further work is
required for the validation of some of the transcription factor consensus sites, and to demonstrate a
functional impact on expression. Further investigation may also examine the temporal regulation
across development and the relationship to various stimuli. In addition, although many of the above
described factors such as CREB, Egr family members, and MeCP2 have been implicated in the response
to substance use, studies have not yet examined how these factors may regulate GABAA R expression
in the maladaptive plasticity that contributes to the development of substance use disorder.
2.2. Translation
Following the production of mRNA via transcription, the translation of mRNA into a protein
product provides further regulation of gene expression. The translation of mRNAs is a multistep
process influenced by a variety of proteins, as well as by features such as the length and structural
stability of the 30 -UTR, the amount of mRNA binding sites, and adenylate–uridylate-rich (AU) elements
at the 30 -UTR [55,56]. mRNA is assembled into ribonucleoprotein particles consisting of mRNAs
and a variety of RNA-binding proteins (RBPs), and the release of mRNA from their cognate RBPs
allows for the translation to commence [57,58]. Recent studies have vastly expanded the number
of known RBPs by identifying non-canonical RNA-binding domains [59]. The transcriptome-wide
identification of RBP mRNA has revealed that most RBP binding occurs in the 30 UTR of transcripts [60].
In comparison with the rest of the mouse 30 -UTRome, GABAA R subunits have a significant increase in
the length of their 30 -UTR [55]. An increase in 30 -UTR length is associated with decreased translational
activity in HEK cells and human neurons [55,61,62] suggesting a high degree of control over GABAA R
subunit expression. The length of the 30 -UTR is also extended during development, which indicates
an increased translational regulation in mature neurons as compared to developing ones. mRNA for
GABAA R subunit proteins, scaffold proteins, and transport proteins have been identified as targets for
RBPs (Figure 2) [55].
The RBP Pumilio2 (Pum2) is a posttranscriptional regulator that binds an eight-nucleotide
consensus sequence in the 30 -UTR of its target mRNA [63]. In a Pum2 knockdown model with
characteristics of epilepsy, GABRA2 mRNA was upregulated two-fold [63]. Prior studies have shown
that Pum2 recruits a deadenylase complex that promotes RNA decay, which suggests that mRNA for
the α2 subunit may become more stable in the absence of Pum2, leading to increased expression [63].
The non-POU domain-containing octamer-binding protein (NONO) is a DNA- and RNA-binding
protein from the Drosophila behavior/human splicing (DBHS) family of proteins. Mutations in the gene
encoding NONO have been linked to intellectual disability in humans [64]. NONO is a member of a
neuronal RNA transport complex [57] and is localized to synapses in an activity dependent manner [65].
NONO has been shown to regulate a large number of transcripts, one third of which are synaptic
proteins [64]. The effect of NONO on synaptic protein expression is regulated by its RNA-binding
domain [64]. A reduction in mRNA and α2 subunit protein was detected in the hippocampus of
a mouse model with NONO gene disruption [64]. These findings suggest that NONO may be
an important promoter of α2 subunit mRNA stability and translation. Although no studies have
examined Pum2 and NONO in substance use, other RBPs have been implicated in the development of
substance use disorders [66], suggesting that the regulation of translation may be an interesting target
to explore further.
Fragile X mental retardation protein (FMRP) is a ubiquitously expressed KH-containing RBP that
associates with polyribosomes [67]. FMRP has been shown to inhibit the translation of mRNA by
directly binding to the ribosome and precludes the binding of tRNA and the translation elongation
factors on the ribosome [68]. FMRP has also been suggested to play a role in the trafficking and
localization of mRNA to synaptic sites, as well as in synaptic protein synthesis [69]. Some estimates
suggest that FMRP targets around 5% of nervous system-enriched genes. A CCG trinucleotide repeat
expansion of the 50 -UTR of the fragile X mental retardation 1 (FMR1) gene causes the silencing of
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FRMP, leading to the neurodevelopmental disorder fragile X syndrome [70]. Multiple studies in FMRP
knockout mice show a downregulation of α1, β2 and δ subunit expression [71], as well as a reduction in
mRNA for the α1,3-5, β1-3, γ1,2 and δ subunits with regional specificity [72–74]. Together, these results
suggest that FMRP may be responsible for regulating the trafficking and/or translation of select subunits
of GABAA Rs [55,67], although the mechanism by which FMRP regulates subunit expression remains
unclear. Recent data have also linked FMRP to substance use, with studies indicating that FMRP acts
as a negative regulator of the plasticity induced by exposure to substances [54].
MicroRNAs (miRNAs) are small, non-coding RNAs that bind with 30 UTRs of mRNA and influence
gene expression [75,76]. miRNAs exert control over translation via base pairing with complementary
sequences within mRNAs, and act to silence gene expression via reducing translation efficiency,
destabilizing mRNA, or causing the cleavage of mRNA. In silico analysis predicted binding sites
for known miRNAs on the 30 UTR of mRNAs for multiple GABAA R subunits [77]. These studies
predicted at least six binding sites for miRNAs in α1 mRNA, the most abundant number of sites of
any of the α subunits [77]. In these studies, no binding sites were predicted for α2 or 3, and only
miRanda predicted sites in α4 and 5 [77]. There were multiple miRNA binding sites predicted in
mRNA for β1-3 subunits [77]. The γ2 subunit was predicted to have two sites [77]. In general, the most
commonly expressed subunits had the most miRNA binding sites predicted, and those subunits with
a more restricted expression had fewer sites, possibly due to shorter 30 UTRs [77]. Experimentally,
the mRNA encoding the α1 subunit has been shown to be regulated by miR-181a, and increasing levels
of miR-181a downregulate α1 subunit expression [78]. The expression of miR-186, miR-24, or miR-375
has been shown to downregulate α4 expression [79]. miR-203 has been shown to reduce luciferase
activity-reporting 30 UTR activity in mRNA encoding the α5 subunit [80]. Evidence is accumulating
for miRNAs as regulators of GABAA R subunit expression, although a number of details remain to
be resolved. Evidence has also accumulated for the support of a role of miRNA regulation of gene
expression in substance use disorders [81–83], which we will discuss in more detail below.
3. Experience-Dependent Plasticity Regulates GABAA Receptor Subunit Expression
The ability to continuously adapt to external and internal stimuli is a unique property of the
nervous system. The brain is known to adapt to physiological as well as pathological contexts by
regulating synaptic connectivity and signaling as a primary response mechanism. Several lines of
evidence have demonstrated overlap between the mechanisms regulating plasticity downstream of
learning and memory, with the plasticity that is involved in responding to substance use and the
development of substance use disorders.
It is well established that synapses are dynamically regulated by neuronal activity [84–87].
While many studies have examined experience-dependent excitatory synapse plasticity, less is known
about the molecular mechanisms that regulate inhibitory synapses [88,89]. Sensory experience controls
multiple steps in the development and refinement of the mammalian brain, many of which stem from
the release of glutamate at excitatory synapses and ultimately result in changes in the strength and
number of synapses [84,86,88]. The number and strength of inhibitory synapses is in turn influenced
by sensory input, as well as the level of excitatory activity, in order to maintain homeostasis [88,90–92].
Dynamic regulation of GABAergic inhibition is likely essential to maintaining homeostasis while
allowing the network to adapt [93].
CREB is well established to be central in the mechanisms of neuronal plasticity. CREB is a
transcription factor that binds to sequences within DNA known as cAMP response elements (CRE),
which are found in the 50 UTR of a large number of genes. The production of cAMP or increased
intracellular Ca2+ activates kinases, that in turn phosphorylate CREB and activate it. Phosphorylated
CREB binds the CRE and interacts with the coactivator CREB-binding protein (CBP), which leads to
the recruitment of histone acetyltransferases to the promoter. As mentioned above, multiple GABAA R
subunit genes have consensus sites for CREB binding in their promoter regions. Other downstream
targets of CREB activation include immediate early genes (IEGs) that act as a gateway to further
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genetic regulation. IEG transcription factors such as c-Fos, c-Myc, and c-Jun are widely known as
ubiquitous regulators of cell growth and differentiation. Given that the nervous system is continually
regulated by stimuli and experience, it is not surprising that a number of IEG transcription factors
have been identified and characterized in neurons. Activity-regulated cytoskeleton-associated protein
(Arc) and Egr-1, among other IEG transcription factors, have been shown to reflect changes in neuronal
activity caused by sensory experience, and their upregulation has been used as a proxy to determine
neuronal activity [94,95].
The IEG brain-derived neurotrophic factor (BDNF) is a downstream target of CREB, and is
established as a key regulator of GABAA R subunit expression. BDNF drives the CREB regulation of
α1 subunit transcription by activating the Janus kinase (JAK)/signal transducers and activators
of transcription (STAT) pathway. The JAK/STAT pathway regulates the expression of BDNF,
which ultimately represses GABRA1 transcription via CREB/ICER binding to the 50 UTR [32]. BDNF also
modulates expression of the α4 subunit through activating the protein kinase c (PKC)/mitogen-activated
protein kinase (MAPK) pathway and modulating levels of Egr3. In addition to α1 and 4 subunits,
BDNF is also implicated in modulating the expression of α2, β2, β3, and γ2 subunits [96]. BDNF is
a well-known contributor to neurodevelopment, as well as to plasticity induced by learning and
memory [97], and substance use [98,99].
More recently, the IEG transcription factor neuronal PAS domain protein 4 (NPAS4) has gained
attention as an important regulator of inhibitory synaptic connectivity downstream of neuronal
activity. NPAS4 is expressed exclusively in response to membrane depolarization, making it explicitly
experience-dependent [88,89]. In hippocampal pyramidal neurons, NPAS4 regulates inhibitory
synapse number through biasing inhibitory synaptic input to the cell body, away from the apical
dendrites. This effect on subcellular targeting has been shown to be mediated by the NPAS4 target
gene BDNF [100]. Sensory enrichment increases NPAS4 levels in CA1 of the mouse hippocampus,
and recruits synapses made by inhibitory cholecystokinin (CCK) basket cells, but not parvalbumin
basket cells [100]. Increasing the number of contacts from CCK basket cells presumably results in the
increased expression of GABAA Rs, that are enriched at these sites on the pyramidal cell soma, but the
mechanisms of this subunit regulation remain to be elucidated.
4. Substance Use Regulates GABAA Receptor Subunit Expression
Persistent substance use induces pathological plasticity in the brain’s reward system and converts
the normal reinforcement of homeostatic behaviors into compulsive drug seeking. Broadly, substance use
disorder is defined as an inability to control the use of a substance or drug, either illegal or legal,
despite harmful consequences. Substance use disorders are diagnosed in the fifth edition of the
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) by 12 criteria that include hazardous use,
neglecting major roles to use, tolerance, withdrawal, and cravings, amongst others [101]. Meeting more
than two criterion constitutes a substance use disorder, with the severity increasing as more criteria
are met. Tolerance refers to the adaptive response of the body and the nervous system to repeated
substance use, where reduced responsiveness is seen for successive equal doses. Withdrawal occurs
upon the abrupt removal of the substance, and involves key motivational elements such as chronic
irritability, emotional pain, malaise, dysphoria, stress, and loss of motivation for natural rewards [102].
Repeated use of commonly abused substances causes positive reinforcement through dopamine (DA)
signaling in the mesolimbic pathway, primarily from the ventral tegmental area (VTA) to the medial shell
of the nucleus accumbens (NAc) [103,104]. This pathway is implicated in the reinforcing effects of abused
substances, as well as natural reinforcers such as food [103,105]. Repeated substance use potentiates
excitatory afferents onto DA neurons in the VTA, and can cause synaptic plasticity in the NAc [106].
Circuit adaptations also induce the aversive response to the abrupt termination of long-term drug
use through stress mediators such as corticotropin-releasing factor and noradrenaline in the extended
amygdala, as well as adaptations by the NAc [103,105]. Transcriptional and post-transcriptional gene
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regulation are thought to play a large role in the changes in brain function related to developing and
maintaining substance use disorders [55,107].
Despite a lack of direct action on DAergic signaling, many of the drugs that positively modulate
GABAA Rs are prone to abuse. The action of GABA on GABAA Rs is well known to be modulated
by a variety of pharmacologically and clinically important drugs including benzodiazepines (BZs),
barbiturates, steroids, and anesthetics [2]. Generally, these drugs act as positive allosteric modulators
(PAMs) at unique sites on the GABAA R, resulting in alterations to the effects of GABA binding [108].
BZs typically act as PAMs of GABAA Rs by binding to a specific BZ site in the extracellular domain
between α and γ subunits [108]. GABAA Rs are also the targets of general anesthetics such as propofol,
etomidate, and halothane, with different anesthetics possessing distinct subunit selectivity and binding
sites [108,109]. Alcohol is also thought to act upon GABAA Rs, stemming from the sensitivity of the
GABA inhibitory Cl- current to alcohol use at low doses (≤30 mm), although some controversy exists
about the precise mechanism of the modulation [108,110–112]. Many studies have examined the action
of GABAA R PAMs, yet many questions remain about how the positive modulation of GABAergic
signaling leads to the activation of the DAergic reward pathway, and the precise role for GABAergic
signaling in the development and maintenance of substance use disorders.
4.1. Benzodiazepine Use
GABAA Rs are the primary binding sites for BZs, which are commonly used to treat disorders
such as anxiety, insomnia, and epilepsy [113]. GABAA Rs composed of α (1,2,3, or 5), along with
β and γ subunits, are considered BZ-sensitive receptors [114]. BZs modulate the Cl− conductance
of GABAA Rs by increasing the frequency at which the ion channel opens [115]. BZs are highly
prescribed but are associated with a number of side effects, and also display a rapid development of
tolerance, produce dependence and withdrawal symptoms, and are commonly abused substances.
The development of tolerance, dependence, and withdrawal have been associated with changes in
GABAA R expression, binding, and function (summarized in Table 1).
Table 1. Summary of the regulation of GABAA receptor subunits with benzodiazepine (BZ) and alcohol
use, and withdrawal.
Benzodiazepine (BZ) Use

Alcohol Use
•

•

↓ GABAA R α1 and γ2 subunit mRNA with
chronic exposure [116]
↓ acetylated histone HC at α1 subunit promoter
and ↑ HDAC 1 and 2 [117]
↑ α4, ↓ α1, ↓ γ2 mRNAs upon withdrawal [118]

•

↑ GABAA R uncoupling at BZ site [124,125]

•

↑ α4 ↓ α1, and ↓ γ2 total protein upon
withdrawal [118]

•
•

↑ GABAA R internalization [113]
↓ GABAA R α2 surface expression with 24 h
exposure [113]

•
Transcription

Post-Translational Modification

•

Total Expression

Surface Expression

•
•
•

↑ increase BDNF (known regulator
of subunit transcription) [119]
↑ α1 mRNA in frontal cortex of
human alcoholics [120,121]
↓ α1 and ↑ α4 mRNA chronic
exposure [122]
↑ α2, α3, and α4 subunit mRNAs
upon withdrawal [123]

•

↓ β subunit and γ2 subunit
phosphorylation [120]

•

↑ α2 expression and ↓ α1 and ↓ γ2
with acute and chronic doses [126]

•

↑ GABAA R internalization [120]

With BZs, the tolerance to anxiolytic effects has been shown 48 hours after even a single dose
of lorazepam in mice [127]. The mechanisms underlying the development of tolerance are still not
completely known, but altered GABAA R subunit gene expression downstream of repeated BZ use has
been demonstrated. GABAA R subunit expression measured by quantitative real-time PCR during
the chronic administration of BZs in vivo demonstrated a 50% decrease in the levels of cortical α1
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subunit mRNA after 14 or 28 days of administration of the full PAM lorazepam [116]. In contrast,
fewer lorazepam administration days (1, 2, 4, 7, and 10) did not modify α1 subunit mRNA [116].
The γ2 subunit mRNA shows a similar time-course and level of reduction in response to chronic
lorazepam treatment [116].
Epigenetic mechanisms may be involved in the downregulation of GABAA R subtypes that lead to
the development of tolerance, particularly to full PAMs that have been well established to elicit these
changes, through DNA methylation, histone acetylation and methylation, chromatin modifications
and other lesser understood mechanisms [117]. Epigenetic regulation of gene expression is implicated
in psychiatric disorders, including substance use disorders, as well as in nervous system adaptations
to substance use such as tolerance, dependence, and withdrawal [128]. The partial PAM imidazenil
does not produce tolerance for the anti-convulsant effects of BZs with chronic use and does not lead to
a decreased expression of mRNA for the α1 subunit seen with full PAMs [117]. The lack of effect on α1
subunit expression with partial PAMs may be due to differences in histone acetylation at the promoter
region upstream of GABRA1 [117]. The full PAM diazepam showed decreased acetylated histone
H3 at the promoter, and increased MeCP2 occupancy in the promoter region [117]. The decrease
in H3 acetylation was due to an increase in the expression of histone deacetylase (HDAC) enzymes
HDAC1 and HDAC2 [117]. Class I HDACs are often found in a complex together with MeCP2 that
acts as a transcriptional repressor at the promoter of a gene, suggesting a possible mechanism of α1
subunit downregulation when given a chronic administration of full PAMs at the BZ site [117,129,130].
The assessment of total acetylated histone H3 protein verified that the chronic use of diazepam was
not reducing the overall H3 protein levels in the cortex, and the reduction was specific to that bound to
the promoter for GABRA1 [117].
Beyond subunit expression, multiple studies have shown evidence for the uncoupling of
GABA and BZ binding sites wherein allosteric enhancement is reduced without changes in binding
affinity [113,131–133]. When the full PAM diazepam or partial PAM Ro 16 6028 are administered,
rat neurons in vitro showed a 50% reduction in receptor sensitivity when administered GABA [134].
Early experiments used embryonic chick neuronal cultures to show a similar rapid development of
tolerance to the BZ flurazepam via uncoupling of about 34% in 18h [131]. An experiment in which rat
cultured cortical neurons were administered diazepam for 48 h and measured for potentiation via a
binding assay showed the uncoupling of the sites [135]. Furthermore, uncoupling was prevented by
use of the BZ site antagonist flumazenil, or picrotoxin, a GABAA R channel blocker, or nifedipine, an
inhibitor of L-type voltage gated Ca2+ channels, all pointing towards a mechanism that involves the
binding of diazepam to a specific site and the subsequent activation of a GABAA R.
The surface level of postsynaptic GABAA Rs is related to the strength of synaptic inhibition and is
modulated by regulated trafficking steps to and from the plasma membrane. Receptor removal,
degradation, insertion and diffusion have all been shown to be dynamically regulated [136].
Jacob et al. looked at GABAA R surface levels after treatment with the BZ flurazepam, and demonstrated
a dramatic decrease in α2 subunit-containing GABAA R surface expression along with total levels of
the subunit [113]. BZ treatment did not alter the insertion and endocytosis rates of α2-containing
GABAA Rs, but did promote degradation, which was reversed by blocking lysosomal degradation [113].
This loss in total GABAA R levels may begin the series of adaptations that contribute to tolerance,
as degradation occurs over the first 24 h of treatment.
4.2. Alcohol Use
Alcohol use produces anxiolytic, anticonvulsant, sedative-hypnotic, cognitive-impairing,
and motor coordination-impairing properties, similar to other drugs that act on the GABAergic
system. The mechanisms behind the effects of alcohol include direct and indirect effects on GABAA Rs,
as well as modulation of GABA release and the synthesis, and availability of endogenous neuroactive
steroids [120], as well as actions on other neurotransmitter systems. Research on the exposure to
alcohol has shown that there has to be epigenetic mechanisms involved in alcohol use and the
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development of alcohol use disorder [137,138]. In search of a reliable bio-marker for chronic alcohol use,
an epigenome-wide association study was performed looking at the differing methylation of CpG sites
in relation to alcohol consumption levels across 13 different cohorts [139]. They found 144 CpGs to be
associated with alcohol consumption, and that epigenetic changes in GABAA R and GABAB R subunit
genes were significantly associated with the expression level of a number of genes that are involved
in immune function [139]. Of the CpGs most significantly tied to alcohol use, cg04781796 is located
on a CpG island intronic to the GABAA R δ subunit (GABRD), and cg09577455 is located on a CpG
island intronic to the GABAB R subunit 1 (GABBR1), and both are implicated in immune function [139].
Similar to BZs, the modulation of histone acetylation caused by a decrease in HDAC activity is seen with
alcohol use, and is thought to take part in the anxiolytic effects of alcohol consumption [119]. The CREB
target-genes BDNF, Arc, and neuropeptide Y are all increased in the amygdala with acute alcohol
exposure [36], and may initiate cascades that result in the regulated expression of GABAA R subunits.
Long-term alcohol administration has been shown to cause differential changes in the expression
of GABAA R subunit mRNA and protein levels in various brain regions (summarized in Table 1) [120].
mRNA for the α2 subunit is down-regulated in the central amygdala of human alcoholics [140].
RT-PCR studies in humans have shown increased α1 expression in the frontal cortex of alcoholics,
as well as total α subunit concentration compared to controls [120,121,141]. In contrast, rodent studies
have shown a decrease in α1 expression and an increase in α4 expression with chronic alcohol
exposure [120,122,126]. In a chronic intermittent ethanol (CIE) rat model, as well under acute alcohol
doses, α2-containing GABAA Rs are upregulated in the hippocampus, basolateral amygdala, and NAc,
all of which are implicated in regulating addiction [126]. Chronic exposure to alcohol in cynomolgus
macaques reduces mRNA for α2 and α3 subunits, and increases α1 subunit mRNA in the basolateral
amygdala [142]. Chronic alcohol exposure also affects GABAA R subunit mRNA expression in different
cortical areas of cynomolgus macaques [143]. mRNA for α2, α4, β1, β3, γ1 and γ3 subunits are
significantly reduced in the orbitofrontal cortex, while β1, β2, γ1 and δ subunit mRNAs are reduced in
the dorsolateral prefrontal cortex [143].
Rodent mutant models lacking specific GABAA R subunits show changes in physiological and
behavioral responses to alcohol consumption [144–149]. α1-null mutant mice show a decrease in
alcohol consumption and an increased aversion to alcohol [144]. α1 and β2 null mutants experience
changes in the sedative effects of alcohol and display shorter periods of loss of righting reflex following
consumption [145]. α1 and β2 knockout mice also show increased locomotor stimulant effects
from alcohol exposure [144,146,147]. A knockdown for α2 also displays a reduction in binge-like
drinking [149]. Using viral-mediated mRNA interference to reduce α4 subunit expression in the NAc
shell has been shown to reduce alcohol consumption at low-to-moderate doses, indicating that the
α4 subunit may be involved in developing a preference for alcohol [150]. Mice lacking the δ subunit
exhibit less of a preference for voluntary alcohol consumption [148]. δ subunit knockout mice also have
reduced hyperexcitability from withdrawal after chronic alcohol exposure [148]. Studies in animal
models and human alcohol use disorder populations, combined with genetic association in families
with multiple alcoholics, identify the regulation of GABAA R α subunit expression as a contributor to
alcohol use disorder [151,152].
miRNAs and other non-coding RNAs are emerging as targets in substance use disorders stemming
from their role in experience-dependent synaptic plasticity [76,137]. miRNA analysis in frontal cortex
tissue from human subjects with alcohol use disorder revealed the upregulation of about 35 miRNAs
compared to the controls [153]. Target prediction and classification suggested that mediators of
synaptic plasticity are major targets of the detected miRNA alterations [153]. Similarly, in animal
models of chronic alcohol exposure, alterations in the expression of over 100 mRNAs and ~30 miRNAs
were detected with some regional specificity [154]. Gene ontology and pathway analysis suggested
that major targets were involved in synaptic plasticity among other cell signaling pathways [154].
Although GABAA R subunits have not been identified as major targets of miRNA alterations in chronic
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alcohol exposure, related pathways and known regulators such as BDNF have been identified across
multiple studies.
In addition to the regulation of expression levels, chronic alcohol exposure has shown a
reduction in α1 subunit-containing GABAA R surface expression in both the cerebral cortex and
the hippocampus [155]. An experiment in cultured rat neurons from the cerebral cortex showed
a dose-dependent (50 mm) reduction in surface α1 subunit-containing GABAA Rs after 4h of acute
ethanol exposure as measured by biotinylation and Western blotting [156]. The 4 h exposure also
reduced the GABAergic response to the subunit selective PAM zolpidem, further showing a functional
impact of reduced surface expression [156]. The mechanism behind the internalization of GABAA Rs
has been linked to alterations in the expression and localization of protein kinase C (PKC) [156].
Phosphorylation is a well-known regulator of GABAA R function under various physiological and
pathological conditions [157–159], including alcohol use disorder [160]. GABAA Rs have a consensus
site for protein kinases PKA and PKC, located on the β subunit whose phosphorylation can lead to
changes in GABA binding, conductance, and possibly internalization [161,162]. A PKC activator
mimics the effects of ethanol exposure on GABAergic signaling, and produces a similar reduction in
surface level receptors [156]. The internalization of α1 subunit-containing GABAA Rs was prevented
by combining the PKC inhibitor calphostin C with ethanol exposure [156]. Immunoprecipitation in
conjunction with ethanol administration showed increased association between α1 subunit and PKCγ,
but not PKCβ [156]. In addition, mice lacking the isoform PKC show an increased behavioral response
to ethanol through reduced γ2 subunit phosphorylation [163].
4.3. Use of Other Highly Abused Substances
While stimulant drugs do not directly bind to GABAA Rs, the use of stimulants including
nicotine [164,165], cocaine [166–168], and amphetamines [169] has been associated with changes in
GABAA R subunit expression. With similarity to families with alcohol use, several single nucleotide
polymorphisms in GABRA4 and GABRA2 have been linked with an increased likelihood for nicotine
dependence [164]. The α2 subunit is thought to lead to nicotine dependence by the activation of
Toll-like receptor 4 in VTA neurons, leading to the activation of CREB and the upregulation of
corticotropin-releasing factor and tyrosine hydroxylase, which play a role in the sensitization to and
reinforcing effects of nicotine [165]. In samples from the hippocampus of human cocaine addicts,
GABRG2 is down-regulated along with the gene encoding the GABAA R-associated protein gephyrin
(GPHN) [168]. GABRG2 and GPHN are both up-regulated in the hippocampus of alcohol-preferring
rats, which also show increased nicotine self-administration and cocaine-seeking behaviors [168].
Other studies have shown that the deletion of the GABRA2 gene abolishes the ability of cocaine to
facilitate conditioned reinforcement [166]. In animal models, α2 subunit levels are decreased in the
NAc shell with sensitization to cocaine, but not the NAc core [167]. Sensitization to methamphetamine
in rats leads to decreased α2 expression in the NAc core and shell, and increased expression in the
caudate nucleus [170]. Methamphetamine-sensitized rats also show the upregulation of mRNA for α3
and β1 subunits in the prefrontal cortex [169].
In addition to stimulant use, there are indications that opiate exposure may also induce alterations
in GABAA R subunit expression [171]. A microarray study of gene families suggests a mix of
the induction and repression of specific subunits in the NAc during a 14-day morphine exposure
paradigm [172]. Overall, α and β subunit expression was somewhat repressed, while γ, δ, and ε subunit
expression was enhanced, particularly around 8 days of morphine exposure [172].
4.4. Withdrawal
As we have described above, GABAA R expression and function have been shown to change in
response to substance use, and contribute to tolerance and the development of substance use disorder.
Withdrawal from an abused substance has also been shown to modify the expression and function of
GABAA R subunits [123]. To observe the effects of withdrawal, hippocampal neurons in culture were
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given 5 days of continuous exposure to ethanol followed by a non-ethanol medium for 3–24 h, and mRNA
levels, neuronal morphology, and the functional and pharmacological responses of GABAA Rs were
examined. Ethanol treatment alone induced decreases in mRNAs for α1, α3, α4, and α5, as well as two
variants of the γ2 subunit, while not causing a change in α2 mRNA levels [123]. During withdrawal,
however, α2, α3, and α4 all significantly increased, peaking at around 3 h after alcohol removal,
while α1 and γ2 subunits had returned to baseline by 9–12 h after ethanol removal [123]. To observe the
pharmacological responses during withdrawal, cultured neurons were incubated in media containing
compounds shown to reduce withdrawal symptoms in human subjects with alcohol use disorder and
alcohol-dependent laboratory animals, including diazepam, gamma-hydroxybutyrate, or the GABAB R
agonist baclofen. Both diazepam and gamma hydroxybutyrate mitigated the withdrawal-induced
increase in α2, α3, and α4 subunits [123]. The BZ diazepam, a full PAM, also shows increased α4
mRNA and total protein upon 6 h of withdrawal, coupled with decreases in α1 and γ2 subunits [118].
Interestingly, the partial PAM imidazenil that does not cause robust changes in subunit expression
during use, still causes a comparable increase in α4 expression and decreased α1 and γ2 expressions
during withdrawal [118]. In addition to withdrawal from alcohol and BZs, alterations in the expression
of GABAA R subunits have been noted in opiate withdrawal. In morphine-tolerant rats, withdrawal
induced an upregulation of ε subunit mRNA in the locus coeruleus [173], while a microarray study
suggested a relatively broad downregulation of GABAA R subunit genes in the NAc [172]. Between 4
and 18 days of abstinence, there was a repression of the α, β, γ, δ, and ε subunits assayed [172].
These results suggest that changes in GABAA R subunit expression may be a common feature of
withdrawal plasticity.
Withdrawal from alcohol has also been shown to lead to the decreased phosphorylation of CREB,
decreased histone H3 and H4 acetylation, and decreases in BDNF, Arc, and neuropeptide Y in the
amygdala, an area of the brain implicated in the anxiety induced by withdrawal [36]. These changes are
the opposite of what occurs during acute exposure, and are thought to be caused by increased HDAC
activity upon withdrawal [36]. Inhibiting HDAC activity in rats reduces alcohol withdrawal-induced
hyperalgesia, suggesting that epigenetic modifications stemming from withdrawal can also alter
pain processing [174]. Protracted abstinence from chronic alcohol exposure in rats has also revealed
alterations in miRNA levels in the frontal cortex [175]. In this study, over 40 rat miRNAs were
found to be altered in the frontal cortex in the protracted abstinence phase, along with alteration in
approximately 165 mRNAs [175]. Using miRNA–mRNA expression pairing revealed 33 miRNAs
putatively targeting 88 mRNAs, many of which were involved in the regulation of synaptic signaling,
including BDNF [175].
Taken together, these data clearly support an alteration in GABAA R expression as a downstream
effect of substance use, as well as in response to withdrawal from an abused substance. In addition,
changes in GABAA R subunit expression are not only seen with exposure to substances that directly act
on the GABAergic system, but also with exposure to other highly abused substances like stimulants
and opiates. The changes in GABAA R subunit expression vary by subunit, substance under study,
experimental paradigm, time point, and brain region, adding much complexity to the picture.
Changes in specific brain regions such as the NAc and VTA are associated with drug reward,
while changes in cortical areas such as the prefrontal cortex, may be related to drug seeking and
choice behaviors. The mechanisms that lead up to the changes in GABAA R expression are diverse,
yet some common factors emerge—there is a compelling overlap with the mechanisms and factors that
underly plasticity in response to learning and memory (CREB and BDNF), as well as with factors that
relate to neurodevelopmental plasticity (MeCP2 and FMRP). Regardless of the complexity, changes in
GABAA R expression appear to be a consistent hallmark of the maladaptive plasticity that occurs
with repeated exposure to substances of abuse as well as withdrawal, warranting further detailed
study. Future studies may endeavor to link changes in specific subunits, across multiple brain areas,
in association with specific timepoints following exposure. It will also be important to examine
specific facets of substance use disorder including reward and reinforcement, motivational and hedonic
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influences, as well as contributions from stress and anxiety, which are known contributors to the
complex picture of substance use.
5. Conclusions
GABAA Rs are highly specialized receptors comprised of a variety of subunits that vary in
expression based on their location and function [2,3]. The expression of specific subunits occurs in an
adaptive and plastic manner, responding to stimuli ranging from sensory experience to substance use
and neurodegeneration. Different classes of sunstances such as BZs and alcohol act upon and modulate
the expression of GABAA Rs by altering the expression with regional and subunit selectivity, as well as
altering receptor surface expression [113,116,117,120,122,126,155]. Transcriptional regulation of mRNA
is the most prevalent means of changes in expression, but the factors controlling the transcription
of individual GABAA R subunit genes are not completely known. Due to their clustered position on
their respective chromosomes, GABAA R subunits are thought to have evolved from a single gene,
and most GABAA R subunit genes are flanked with 50 -UTRs that are CpG-rich and lack the canonical
TATA box [1,23,24]. CREB and BDNF are thought to be important and interrelated regulators of the
expression of multiple GABAA R subunits, via multiple signaling pathways [96,176]. Both of these
proteins are well established as key regulators of learning and memory [34,97], as well as in the
plasticity associated with substance use [35,36,98,99].
Post-transcriptional regulation also contributes to the expression of GABAA R subunits.
The 30 UTRrome of the genes coding for α subunits is longer than the general 30 UTRome in mice,
leading to the availability of many binding sites for RBPs and miRNAs to exert the translational
control of expression [1]. A small number of RBPs have been identified to regulate the translation of
GABAA R subunit mRNAs into protein, including Pum2 [63,177], NONO [64,65] and FMRP [55,67–74].
Multiple binding sites for miRNAs have been identified on the 30 UTR of GABAA R subunit genes.
miRNAs are implicated in experience-dependent plasticity at the 30 UTR, and are emerging as a
candidate in the development of substance use disorders by changing the expression of the genes
involved in dependence and withdrawal [75–77,137,138].
BZs and alcohol act upon GABAA Rs, and both cause changes in the expression of subunits,
as well as epigenetic modifications such as increased histone acetylation through the inhibition of
HDACs [36,117,138,174]. The most consistent changes identified across both BZ and alcohol use in
both human subjects and animal models include alterations in the expression of α1, 2, 4, and γ2
subunits [113,116–118,120–123,126,136,141,149,151,155,156]. While changes in the expression and
regulation of multiple subunits has been identified in alcohol use disorder and animal models, the α2
subunit has also been genetically linked to alcoholism [108,149,151,152]. The α2 subunit is known to
mediate the anxiolytic effects of alcohol, and is also upregulated in the amygdala during withdrawal
states characterized by increased anxiety [118,123,174]. The use of other commonly abused substances
such as stimulants also modifies the expression of GABAA R subunits, again with the α2 subunit
identified by genetic, human postmortem and animal model studies [164–172]. While RBP binding sites
have been identified for the α2 subunit, specific miRNAs and RBPs that may be affecting expression
require further examination, particularly in the context of substance use. Identifying the factors
upstream of expression regulation could possibly lead to better, more specific therapies for substance
use disorder targeting the 30 UTR, as well as a further understanding of the factors regulating gene
expression during acute and chronic exposure to drugs, and subsequent withdrawal.
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